HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

FDA Accepts BLA for Trastuzumab Biosimilar in HER2+ Breast Cancer, Gastric/GEJ Cancer

April 5th 2023

The FDA has accepted a biologics license application for the HLX02, a proposed trastuzumab biosimilar, as adjuvant therapy for patients with HER2-overexpressing breast cancer, HER2-overexpressing metastatic breast cancer, and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma

Integrating New Standards for Metastatic HER2+ Breast Cancer

March 20th 2023

The first-line standard of care for patients with HER2-postive metastatic breast cancer has long been held by the combination of pertuzumab, trastuzumab, and a taxane established with the publication of data from the CLEOPATRA trial.

Response-Guided Therapy Is the Next Frontier for Tailoring Therapy in HER2+ Breast Cancer

March 10th 2023

Lisa M. Carey, MD, ScM, FASCO, discusses upcoming treatments that could impact standard-of-care practices and the continually evolving role of antibody-drug conjugates role in the breast cancer treatment paradigm.

Predictive, Prognostic Models May Tailor Neoadjuvant Approach in HER2+ Breast Cancer

March 3rd 2023

With the advent of effective drug regimens to treat HER2-positive breast cancer, the use of tailored efforts with neoadjuvant therapy in this space may continue to improve efficacy moving forward.

HER2-Low Expression is the Tip of the Iceberg in Breast Cancer Classification

March 3rd 2023

The advent of antibody-drug conjugates has placed a renewed focus on the lesser thought of HER2 classifications of IHC 1+ and 0.

ARX788 Meets PFS End Point in HER2+ Metastatic Breast Cancer

March 1st 2023

The antibody-drug conjugate ARX788 was found to significantly improve progression-free survival compared with an active control in patients with HER2-positive locally advanced or metastatic breast cancer.

Trastuzumab Deruxtecan Garners Approval in China for HER2+ Metastatic Breast Cancer

February 24th 2023

The National Medical Products Administration of China has approved the use of single-agent fam-trastuzumab deruxtecan-nxki in adult patients with unresectable or metastatic HER2-positive breast cancer who previously received 1 or more anti–HER2-based regimens.

Real-World Analysis May Clarify Role of Adjuvant Endocrine Therapy in Premenopausal HER2+ Breast Cancer

February 24th 2023

Jasmine Sukumar, MD, discusses the purpose of analyzing endocrine therapy use in HR-positive/HER2-positive patients, key data presented from the retrospective analysis at SABCS, and the need for improved understanding of clinical indications for endocrine therapy in this breast cancer subtype.

Old Standards Are Revisited in HER2+ Early-Stage Breast Cancer

February 23rd 2023

As targeted agents for various levels of HER2 expression have demonstrated dynamic interoperability and efficacy, the prognosis for HER2-positive disease has improved.

Dr. Crown on the Investigation of Lapatinib Plus Chemotherapy in HER2+ Breast Cancer

February 3rd 2023

John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses the rationale for evaluating lapatinib (Tykerb) with standard trastuzumab/chemotherapy regimen in patients with HER2-positive breast cancer, as well as contextualizes results from a phase 2 trial.

DZD1516 Plus Trastuzumab Deruxtecan Shows Preclinical Synergy in HER2+ Breast Cancer with Brain Metastases

February 1st 2023

Nicholas P. McAndrew, MD, MSCE, discusses the need for HER2-targeted TKIs specifically designed to penetrate the blood-brain barrier, updated clinical data on the safety and tolerability of DZD1516 monotherapy, and the implications of nonclinical data on DZD1516 for treating CNS metastases in HER2-positive breast cancer.

Adjuvant T-DM1 Plus Concurrent Radiation Not Associated With Increased Cardiotoxicity in HER2+ Breast Cancer

January 30th 2023

Mridula George, MD, discusses the methods used to evaluate cardiotoxicity associated with adjuvant trastuzumab emtansine plus concurrent radiation therapy, and explains implications on the use of trastuzumab emtansine plus radiation in patients with early-stage HER2-positive breast cancer.

European Commission Approves Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer

January 26th 2023

Fam-trastuzumab deruxtecan-nxki has received approval in the European Union as a single agent for the treatment of patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

Dr. Vicini on the Potential Utility of the DCISionRT Test in HER2+ DCIS of the Breast

January 25th 2023

Frank A. Vicini, MD, discusses the potential utility of using the DCISionRT test to determine treatment benefit in the phase 3 NRG-NSABP-B43 trial in HER2-positive ductal carcinoma in situ of the breast.

Dr. O’Shaughnessy on DESTINY-Breast02 and DESTINY-Breast03 in Metastatic HER2+ Breast Cancer

January 20th 2023

Joyce A. O’Shaughnessy, MD, discusses key data from the phase 3 DESTINY-Breast02 and DESTINY-Breast03 trials in metastatic HER2-positive breast cancer.

Dr. Dhakal on the Evolution of Pertuzumab Regimens in HER2+ Breast Cancer

January 18th 2023

Ajay Dhakal, MBBS, discusses the two key trials supporting the use of pertuzumab as a standard-of-care regimen in HER2-positive breast cancer.

Neoadjuvant Anti-HER2 TKIs Require Further Investigation for HER2+ Breast Cancer

January 17th 2023

John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses previous research with anti-HER2 TKIs in HER2-positive breast cancer, expanded on key follow-up data from this phase 2 trial, and emphasized the importance of continued investigation into this underutilized combination.

Dr. Dhakal on the Implementation of Trastuzumab Deruxtecan Across the HER2+ Breast Cancer Landscape

January 12th 2023

Ajay Dhakal, MBBS, discusses the evolution and implementation of the antibody-drug conjugate trastuzumab deruxtecan across the landscape of HER2-positive breast cancer landscape.

Real-World Analysis Shows Low Use of Ovarian Suppression in Premenopausal HR+/HER2+ Breast Cancer

January 9th 2023

Maryam Lustberg, MD, MPH, discusses key results from a retrospective analysis of ovarian suppression in HR–positive, HER2-positive breast cancer, the importance of assessing real-world practice patterns, and the need for continued study of other predictive biomarkers for endocrine therapy in this population.

Neoadjuvant, Adjuvant Pertuzumab/Trastuzumab Regimen Continues to Have Clinical Benefit in Early or Locally Advanced HER2+ Breast Cancer

December 30th 2022

Neoadjuvant and adjuvant pertuzumab plus trastuzumab with docetaxel continued to show improvements in event-free survival, disease-free survival and overall survival vs trastuzumab/docetaxel and placebo in Asian patients with HER2-positive early or locally advanced breast cancer.